Stocks TelegraphStocks Telegraph
Stock Ideas

LLY Company Profile and Key Details

NYSE : LLY

Eli Lilly and

$1,021.59
33.5+3.39%
At Close 4:00 PM
70.76
B+ESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Eli Lilly and Company (LLY) stock surged +3.39%, trading at $1,021.59 on NYSE, up from the previous close of $988.09. The stock opened at $988.72, fluctuating between $984.60 and $1,021.63 in the recent session.

Stock Snapshot

988.09
Prev. Close
962.07B
Market Cap
984.6
Day Low
36.3
P/E Ratio
28.14
EPS (TTM)
-3.32
Cash Flow per Share
988.72
Open
941.74M
Number of Shares
1021.63
Day High
99.56%
Free Float in %
11.35
Book Value
2.53M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
May 19, 2026989.511,021.80984.601,021.413.8M
May 18, 20261,000.611,003.00978.87988.092.02M
May 15, 20261,006.981,014.38997.411,004.922.79M
May 14, 20261,017.491,018.17996.011,006.701.75M
May 13, 2026994.751,022.82992.001,015.753.48M
May 12, 2026974.44997.52971.18989.873.02M
May 11, 2026949.00995.00943.26966.993.52M
May 08, 2026974.07980.00947.51948.452.96M
May 07, 2026985.37989.00967.10974.963.35M
May 06, 2026991.35996.49983.50987.053.92M
May 05, 2026971.89992.80964.41988.872.95M
May 04, 2026960.00974.22951.76967.933.65M
Apr 30, 2026898.78945.50896.80934.608.23M
Apr 29, 2026866.04869.02850.51851.213.88M
Apr 28, 2026871.90878.00863.46874.002.56M
Apr 27, 2026878.13891.20868.04868.272.68M
Apr 23, 2026929.49930.00911.89917.652.14M
Apr 22, 2026906.40922.54902.23921.482.62M
Apr 21, 2026910.20913.05881.11903.024.03M
Apr 20, 2026926.90929.64912.50919.901.92M

Contact Details

Indianapolis, IN 46285

United States

https://www.lilly.com317 276 2000

About Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Company Information

Employees47000
Beta0.5
Sales or Revenue$34.12B
5Y Sales Change%0.806%
Fiscal Year EndsDecember
SectorHealthcare
IndustryDrug Manufacturers - General

Stock Peers

JNJ
1.08+0.47%
Johnson & Johnson$230.00ABBV
4.45+2.13%
AbbVie Inc.$213.86AZN
0.72+0.39%
AstraZeneca PLC$184.64NVS
1.29+0.86%
Novartis AG$150.44MRK
1.71+1.52%
Merck & Co., Inc.$114.27BMY
1+1.74%
Bristol-Myers Squibb Company$58.31GSK
0.79+1.57%
GSK plc$51.05NVO
00
Novo Nordisk A/S$44.28PFE
0.35+1.38%
Pfizer Inc.$25.68OGN
-4.19617e-70.00%
Organon & Co.$13.42

Company Overview

The stock is currently mid-range between its 52-week high and low $623.78 and $1.13 thousand. With a market capitalization of about $962.07 billion, Eli Lilly and Company is classified as a mega-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 3.08 million shares, in line with its 52-week average. Headquartered in Indianapolis, IN, Eli Lilly and Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO David A. Ricks, the company employs approximately 47,000 people and listed since June 01, 1972. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -1.25%, SMA50 -2.97%, SMA200 17.08%). The stock’s 14-day RSI is 46.82 (neutral), while the ATR of 35.82 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -9.87% below its high and over 63.84% above its low. Average 10-day trading volume of 2.91 million shares is in line with the 3-month average of 3.03 million, indicating normal recent market interest.

Valuation Metrics

Eli Lilly and Company trades at a P/E ratio of 35.94, slightly above the S&P 500 average, with a price-to-sales ratio of 13.24 and a price-to-book ratio of 29.11 reflecting a rich premium to book value. The P/FCF stands at 70.42, also above market averages. Compared to sector medians, Eli Lilly and Company P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Eli Lilly and Company last paid a dividend of 6.92 per share, this equals a trailing yield of roughly 0.55%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $708.49. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Eli Lilly and Company generated EPS of $22.59 over the past year. Five-year average earnings growth is 27.59%. Wall Street analysts project EPS growth of 26.77% annually over the next five years. The latest quarter delivered EPS of $8.55. The next quarter is forecast at $7.21. Next year's EPS is expected at $86.83. Analyst sentiment is bullish. Analyst rating data shows there are 23 Strong Buy ratings, 18 Buy ratings, 3 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 thousand to $1.25. The high target offers 46.83% upside. The low target suggests -99.88% downside. The mean target is $1.07 thousand. This offers 4.98% upside. Eli Lilly and Company earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 30, 2026, missed forecasts by 22.67%. The prior quarter beat by 9.12%. Over the last six quarters, Apple has recorded several small beats. These include 5.77% in February 06, 2025.

Shareholding & Insider Activity

Eli Lilly and Company has 896.46 million shares outstanding. The public float is 895.44 million shares, elevated short interest at 0.90% of float. This equals 7.17 million shares. The short ratio is 2.2 days. Institutional investors hold 84.0% of the float. Insiders own 0.16%. LILLY ENDOWMENT INC holds 91.88 million shares, Ricks David A has 546.60 thousand shares and Skovronsky Daniel has 137.66 thousand shares. Over the past six months, insider transactions show net selling. They sold 25.58 thousand shares across 11 transactions.

Price Forecast & Outlook

Our AI price prediction model suggests that Eli Lilly and Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.93%, with price expected at $1.09 thousand by June 02, 2026, within a range of $1.06 thousand to $1.12 thousand 3-Month Outlook: Projected rise of 6.34%, reaching $1.09 thousand by August 17, 2026, with a range of $1.01 thousand to $1.15 thousand. 1-Year Outlook: Projected gain of 12.21%, with price at $1.15 thousand by May 19, 2027, within a range of $1.10 thousand to $1.18 thousand.

Key Takeaways

Eli Lilly and Company (NYSE:LLY) shares are flat -3.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Eli Lilly and Company trading at a premium to the broader market with a P/E of 35.94. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $750.63, suggesting -26.51% downside. Our AI forecast model points to short-term strength (6.93% over two weeks), a medium-term rise (6.34% over three months), and a longer-term gain (12.21% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Eli Lilly and Company (LLY) stock price?
Eli Lilly and Company (NYSE: LLY) stock price is $1,021.59 in the last trading session. During the trading session, LLY stock reached the peak price of $1,021.63 while $984.60 was the lowest point it dropped to. The percentage change in LLY stock occurred in the recent session was 3.39% while the dollar amount for the price change in LLY stock was $33.50.
LLY's industry and sector of operation?
The NYSE listed LLY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Eli Lilly and Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of LLY?
Mr. Jacob S. Van Naarden
Senior Vice President, Chief Executive Officer of Loxo Oncology & Pres of Lilly Oncology
Mr. Donald A. Zakrowski
Chief Accounting Officer & Vice President of Fin.
Ms. Leigh Ann Pusey
Executive Vice President of Corporation Affairs & Communications
Mr. Alonzo Weems
EVice President of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Patrik Jonsson
EVice President, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology
Mr. Eric Dozier
Executive Vice President of HR & Diversity
Dr. Daniel M. Skovronsky M.D., Ph.D.
Executive Vice President, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories
Mr. Martin Bott MIBS
Vice President of Fin. & Special Projects
Mr. Diogo Rau
EVice President & Chief Information and Digital Officer
Ms. Anat Ashkenazi
Executive Vice President & Chief Financial Officer
Ms. Anat Hakim J.D.
Executive Vice President, Gen. Counsel & Sec.
Mr. David A. Ricks
Chairman, Chief Executive Officer & Pres
How LLY did perform over past 52-week?
LLY's closing price is 63.77% higher than its 52-week low of $623.78 where as its distance from 52-week high of $1,133.95 is -9.91%.
How many employees does LLY have?
Number of LLY employees currently stands at 47,000.
Link for LLY official website?
Official Website of LLY is: https://www.lilly.com
How do I contact LLY?
LLY could be contacted at phone 317 276 2000 and can also be accessed through its website. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, United States.
How many shares of LLY are traded daily?
LLY stock volume for the day was 2.53M shares. The average number of LLY shares traded daily for last 3 months was 3.08M.
What is the market cap of LLY currently?
The market value of LLY currently stands at $962.07B with its latest stock price at $1,021.59 and 941.74M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph